Efficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic- Americans with multiple sclerosis von Zhovtis Ryerson, Lana, Green, Rivka, Confident, Gladyne, Pandey, Krupa, Richter, Benjamin, Bacon, Tamar, Sammarco, Carrie, Laing, Lisa, Kalina, Jennifer, Kister, Ilya

Volltext

Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2) von Wiendl, Heinz, Foley, John, Defer, Gilles, Zhovtis Ryerson, Lana, Cohen, Jeffrey A., Arnold, Douglas L., Butzkueven, Helmut, Cutter, Gary R., Giovannoni, Gavin, Killestein, Joep, Domingo-Horne, Rose, Toukam, Marie, Nunn, Aimie, Maghzi, Amir-Hadi, Kuhelj, Robert, Lasky, Tyler

Volltext

Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—Commentary von Gratch, Daniel, Zhovtis Ryerson, Lana

Volltext

Vaccine-breakthrough SARS-CoV-2 infections in people with multiple sclerosis and related conditions: An observational study by the New York COVID-19 Neuro-Immunology Consortium (NY... von Klineova, Sylvia, Farber, Rebecca Straus, DeAngelis, Tracy, Leung, Tungming, Smith, Tyler, Blanck, Richard, Zhovtis-Ryerson, Lana, Harel, Asaff

Volltext

COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center von Parrotta, Erica, Kister, Ilya, Charvet, Leigh, Sammarco, Carrie, Saha, Valerie, Charlson, Robert Erik, Howard, Jonathan, Gutman, Josef Maxwell, Gottesman, Malcolm, Abou-Fayssal, Nada, Wolintz, Robyn, Keilson, Marshall, Fernandez-Carbonell, Cristina, Krupp, Lauren B., Zhovtis Ryerson, Lana

Volltext

Cellular and Humoral Immunity to SARS‐CoV‐2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease‐Modifying Therapies: A Multi‐Ethnic Observational Study... von Kister, Ilya, Patskovsky, Yury, Curtin, Ryan, Pei, Jinglan, Perdomo, Katherine, Rimler, Zoe, Voloshyna, Iryna, Samanovic, Marie I., Cornelius, Amber R., Velmurugu, Yogambigai, Nyovanie, Samantha, Kim, Joseph J., Tardio, Ethan, Bacon, Tamar E., Zhovtis Ryerson, Lana, Raut, Pranil, Pedotti, Rosetta, Hawker, Kathleen, Raposo, Catarina, Priest, Jessica, Cabatingan, Mark, Winger, Ryan C., Mulligan, Mark J., Krogsgaard, Michelle, Silverman, Gregg J.

Volltext

Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies von Smith, Tyler E, Madhavan, Maya, Gratch, Daniel, Patel, Aneek, Saha, Valerie, Sammarco, Carrie, Rimler, Zoe, Zuniga, Guadalupe, Gragui, Dunia, Charvet, Leigh, Cutter, Gary, Krupp, Lauren, Kister, Ilya, Ryerson, Lana Zhovtis

Volltext

Adult-onset spastic paraparesis: An approach to diagnostic work-up von Zhovtis Ryerson, Lana, Herbert, Joseph, Howard, Jonathan, Kister, Ilya

Volltext

Incomplete Susac syndrome exacerbated after natalizumab von Zhovtis Ryerson, Lana, Kister, Ilya, Snuderl, Matija, Magro, Cynthia, Bielekova, Bibiana

Volltext

It’s Not Always An Infection: Pyoderma Gangrenosum of the Urogenital Tract in Two Patients with Multiple Sclerosis Treated with Rituximab (1795) von Parrotta, Erica, Ryerson, Lana Zhovtis, Krupp, Lauren

Volltext

A Case of Progressive Multifocal Leukoencephalopathy in a Patient on Extended Interval Dose Natalizumab (P5.374) von Gutman, Josef, Ryerson, Lana Zhovtis, Kister, Ilya

Volltext

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing von Ryerson, Lana Zhovtis, Foley, John, Chang, Ih, Kister, Ilya, Cutter, Gary, Metzger, Ryan R, Goldberg, Judith D, Li, Xiaochun, Riddle, Evan, Smirnakis, Karen, Kasliwal, Rachna, Ren, Zheng, Hotermans, Christophe, Ho, Pei-Ran, Campbell, Nolan

Volltext

Association of Disease Severity and Socioeconomic Status in Black and White Americans With Multiple Sclerosis von Gray-Roncal, Karla, Fitzgerald, Kathryn C., Ryerson, Lana Zhovtis, Charvet, Leigh, Cassard, Sandra D., Naismith, Robert, Ontaneda, Daniel, Mahajan, Kedar, Castro-Borrero, Wanda, Mowry, Ellen M.

Volltext

Reduced Risk of Progressive Multifocal Leukoencephalopathy (PML) with Natalizumab Extended Interval Dosing (EID) Compared with Every-4-week (Q4W) Dosing: Updated Analysis of the TO... von Ryerson, Lana Zhovtis, Foley, John, Kister, Ilya, Cutter, Gary, Metzger, Ryan, Goldberg, Judith, Li, Xiaochun, Riddle, Evan, Smirnakis, Karen, Domingo-Horne, Rose, Lasky, Tyler

Volltext

Characteristics and clinical outcomes of underserved minority patients with multiple sclerosis treated with peginterferon beta-1a or intramuscular interferon beta-1a in MS PATHS (2... von Hersh, Carrie M., Fitzgerald, Kathryn, Ryerson, Lana Zhovtis, Mowry, Ellen, Liao, Shirley, Altincatal, Arman, Naylor, Maria

Volltext

Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders von Lotan, Itay, Charlson, Robert W., Ryerson, Lana Zhovtis, Levy, Michael, Kister, Ilya

Volltext

At-Home Transcranial Direct Current Stimulation (tDCS) for Teleinterventions: Safety and Tolerability with Remote Supervision (S10.001) von Pilloni, Giuseppina, Best, Pamela, George, Allan, Lustberg, Matthew, Mirza, Ibraheem, Ryerson, Lana Zhovtis, Krupp, Lauren, Charvet, Leigh

Volltext

No Difference in Disability Progression of MS Patients Treated with Extended Interval vs. Standard Interval Natalizumab (P3.110) von Fallon, Julia, Kister, Ilya, Zhovtis Ryerson, Lana

Volltext

RITUXIMAB AND PREGNANCY IN NEUROIMMUNOLOGICAL DISORDERS: A RETROSPECTIVE STUDY (1939) von Ge, Lily, Kister, Ilya, Charlson, Robert, Howard, Jonathan, Krupp, Lauren, Ryerson, Lana Zhovtis

Volltext

Effectiveness of Subcutaneous Tocilizumab therapy in Neuromyelitis Optica Spectrum Disorder (2287) von Lotan, Itay, Charlson, Robert, Ryerson, Lana Zhovtis, Levy, Michael, Kister, Ilya

Volltext